Novo Halves Ozempic Price to $499 a Month For Those Paying Cash

单集文稿 ...

• 00:02

  Hi, I'm Lisa Mateo, introducing you to the new Stock Movers Report from Bloomberg.

• 00:08

  These are short audio reports, five minutes or less,

• 00:11

  delivered right to your podcast feed throughout the day.

• 00:14

  Stock Movers fills you in on the day's winners and losers on Wall Street and tells you about the news and data that's driving those gains and losses.

• 00:22

  If you want to stay plugged into the stock market but don't want to spend all day watching tickers scroll across your screen,

• 00:29

  then Stock Movers is a place for you to get informed.

• 00:33

  Listen a couple times throughout the day to find out what's moving equities.

• 00:43

  Get the latest stock news and data backed by reporting from Bloomberg's 3,000 journalists and analysts across the globe.

• 00:52

  Subscribe to Stock Movers wherever you get your podcasts.

• 01:09

  You're listening to the Bloomberg Intelligence Podcast.

• 01:12

  Catch us live weekdays at 10 a.m.

• 01:14

  Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App.

• 01:18

  Listen on demand wherever you get your podcasts or watch us live on YouTube.

• 01:24

  We had some FDA approvals.

• 01:25

  They're pushing gains in some pharmaceutical companies, specifically Novo Nordisk.

• 01:30

  So here to break that down and a whole lot more news that's coming out about Novo is Madison Muller.

• 01:35

  She's Bloomberg Health reporter.

• 01:37

  But the big news, so the weight loss drug we go over,

• 01:39

  you got this U.S. approval to treat a form of liver disease.

• 01:43

  So what does this mean for the company?

• 全部文稿